Read twice and referred to the Committee on Finance.
The bill amends the Social Security Act to make the eligibility timing for the Medicare Drug Price Negotiation Program the same for small-molecule drugs and biologics. It sets a 7-year elapsed-time rule for initial price applicability years 2026 and 2027, and requires at least 11 years elapsed since approval for initial price applicability year 2028 and thereafter.
Progressives emphasize delayed price relief and higher beneficiary costs.
Narrow technical change with clear beneficiaries may attract support, but conflicts with broader drug-price reform priorities.
The bill amends the Social Security Act to make the eligibility timing for the Medicare Drug Price Negotiation Program the same for small-molecule drugs and biologics.
It sets a 7-year elapsed-time rule for initial price applicability years 2026 and 2027, and requires at least 11 years elapsed since approval for initial price applicability year 2028 and thereafter.
Technically simple but touches contentious drug-pricing tradeoffs; favored by industry interests but faces policy opposition and must clear both chambers.
How solid the drafting looks.
Progressives emphasize delayed price relief and higher beneficiary costs.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize delayed price relief and higher beneficiary costs.
Likely opposed.
The change delays when many drugs — especially small molecules — become eligible for Medicare negotiation, which could keep prices higher longer.
Supporters' claims about innovation incentives will be viewed skeptically unless paired with safeguards for affordability.
Mixed view.
Appreciates policy consistency and predictability for manufacturers but worries about delayed savings and consumer price effects.
Would seek data and potential guardrails to balance innovation and affordability.
Likely supportive.
Views the bill as protecting incentives for drug development and reducing premature government price intervention.
Sees equal treatment as a pro-innovation, pro-market correction to the original statute.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically simple but touches contentious drug-pricing tradeoffs; favored by industry interests but faces policy opposition and must clear both chambers.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize delayed price relief and higher beneficiary costs.
Technically simple but touches contentious drug-pricing tradeoffs; favored by industry interests but faces policy opposition and must clear…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for EPIC Act of 2025.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.